In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe Withdraws Patent Infringement Lawsuit over Radicut Bag against Nissin Pharmaceutical
January 24, 2018
- AnGes’ Gene Therapy Re-Submitted for CLI, This Time for Conditional Approval
January 23, 2018
- Astellas/Vical’s CMV Vaccine Flops in Global PIII
January 23, 2018
- MSD Files for Once-Daily Isentress in Japan
January 23, 2018
- Huahai’s Japan Arm to Focus on Sales of API, Contract Manufacturing; Planning Sales of In-House Products in 10 Years
January 23, 2018
- Eisai Grants Rights for Cancer Agent E7046 to Chinese Immunotherapy Firm
January 22, 2018
- Mochida’s Enbrel Biosimilar Approved, with Ayumi as Distributor
January 22, 2018
- US Court Rejects Eisai Partner’s Bid for Rehearing on Aloxi Decision
January 19, 2018
- NanoCarrier in Talks for Biz Alliance with Ceolia
January 19, 2018
- Industry Expresses Disappointment about “Expansion” of Essential Drugs; Some Looking to Real Expansion in FY2020
January 19, 2018
- Japan Units of Shire, Baxalta to Merge on Feb. 1
January 19, 2018
- Another Drug Lag “Will” Arise, Says Mitsubishi Tanabe President after JPMA Chief’s Denial
January 19, 2018
- Novartis to Transfer Rasilez to OrphanPacific in Japan
January 18, 2018
- Kissei/JCR’s Nesp Biosimilar Shows Equivalence in Japan PIII
January 18, 2018
- Life Science Institute Launches Clinical Study of IV Regenerative Medicine Product for Acute Myocardial Infarction
January 18, 2018
- Kyowa Kirin Officially Announces Launch of Japan’s 1st Rituxan Biosimilar on Jan. 18
January 18, 2018
- Mitsubishi Tanabe Grabs Add’l Indication for Novastan in China
January 17, 2018
- Toray Grants China License for Remitch OD to 3SBio
January 17, 2018
- Nichi-Iko Teams Up with 2 Philippine Companies
January 17, 2018
- Ethical Drug Sales Up 0.8% in November on Cancer Meds
January 17, 2018
ページ
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…